ClinicalTrials.gg
RecruitingNCT05228262VASCOUpdated Oct 10, 2022

Vascular Function, Sarcopenia and Pain in Postmenopausal Osteoporosis

An interventional study of Cohort follow-up in Osteoporosis, Postmenopausal, sponsored by University Hospital, Clermont-Ferrand. Recruiting at 1 site in France. Open to female participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2022-10-10.

Sponsored by University Hospital, Clermont-Ferrand · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Feb 2022; still recruiting 4 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
50 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 22 studies in Osteoporosis, Postmenopausal with a site in France — 3 open to participants now, 4 under way, none of them phase 3. Osteoporosis, Postmenopausal · France.

Planned enrollment
18th of 19
150 · median 719
Started
2022
with 1 other
No phase
2 of 22
2 open now
Registered
18th of 22
by date
Lead sponsor
2 of 22
University Hospital, Clermont-Ferrand

Among the 22 studies in Osteoporosis, Postmenopausal with a site in France, this one is the 18th largest by planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2022, is one of 2 with no phase, and was the 18th registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

3 of the 22 studies in Osteoporosis, Postmenopausal with a site in France are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 50 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Osteoporosis, Postmenopausal with a site in France, or all of them as a file.
02

Study summary

This study aims to follow a cohort of osteoporotic patients treated with anti-osteoporotic drugs and to evaluate the impact of these treatments on the osteoporosis-cardiovascular-sarcopenia triad and on pain.

Read the detailed description

Exploratory study involving functional explorations in longitudinal follow-up, initiated in parallel with a treatment indicated in the patient's usual care and management.

The main objective is the evaluation of the evolution of the vascular and endothelial function.

The secondary objectives are:

  1. To study the evolution of cardiovascular parameters,
  2. To study the evolution of sarcopenia,
  3. To study the evolution of quality of life and pain,
  4. To study the evolution of bone remodeling (by creating a collection of biological samples),
  5. To study the genetic predisposition of osteoporosis including the confirmation of known genetic markers and the potential identification of new genetic variants involved (by creating a biobank),
  6. To study epigenetic biomarkers in the osteoporosis patient population (by creating a biobank),
  7. To study the role of the microbiota in osteoporosis patients (by creating a biobank),
  8. To study the determinants of the evolution of the studied parameters and to identify trajectories (therapeutic response profiles).

As part of their usual care and management, patients will be diagnosed with osteoporosis and prescribed anti-osteoporotic drugs.

The patients will have six visits: a pre-selection visit that will take place in the Rheumatology Department of the Clermont-Ferrand University Hospital and five visits that will take place in the Clinical Investigation Platform/Clinical Investigation Center (PIC/CIC) Inserm 1405 of the Clermont-Ferrand University Hospital.

Visit 0 - Screening visit and diagnosis of osteoporosis T0-1: Rheumatology Department

During this visit, the investigator physician will perform various examinations and tests usually performed as part of the patient's usual care and management in order to establish a diagnosis of osteoporosis.

These examinations are as follows:

  • Bone densitometry less than one year old using Dual energy X-ray Absorptiometry (DXA),
  • Bone biological assessment, including the following tests: Complete Blood Count (CBC), platelets, C-Reactive Protein (CRP), urea, creatinine with CKD-EPI clearance calculation, liver enzymes (AST, ALT), serum calcium, serum calcium corrected by albumin, serum phosphorus, serum protein electrophoresis, Thyroid Stimulating Hormone (TSH), 25 OH vitamin D, serum CTX (C-terminal telopeptides of type 1 collagen).

Some patients who require profile radiographs of the spine will have this examination added for the consultation, especially for the evaluation of vertebral fractures if the context justifies it. Other patients will also have these x-rays for the calculation of the abdominal aortic calcification score (Kauppila score) by the rheumatologist.

Body composition will be requested during the bone densitometry evaluation on the DXA machine.

Once the diagnosis of osteoporosis is confirmed, the physician will propose to the eligible patients to participate in this research protocol by explaining the objectives and the course of the study, and give them an information note in order to give them a necessary time of reflection of a maximum of one month, depending on the scheduling of the inclusion visit.

If patients are interested,the investigator physician will prescribe osteoporotic treatment to be started after the V1 (T0) inclusion visit.

Visit 1 - Inclusion visit - T0: PIC/CIC (2 hours)

During this visit, the physician will explain again the objectives and progress of the study with the different tests and questionnaires planned so that the patients can give their informed consent to participate.

During this visit, the following will be performed:

  • A medical examination,
  • A blood sample in order to obtain a collection of biological samples for the purpose of:

    1. Assess bone biomarkers (osteocalcin, sclerostin, periostin, irisin, N-terminal propeptide of procollagen type 1 (P1NP), Dickkopf-related protein 1 (DKK1) and C-terminal telopeptides of collagen type 1 (CTX)),
    2. Characterize genetic predispositions to osteoporosis,
    3. Characterize epigenetic biomarkers in the osteoporosis patient population by microRNA analysis,
  • Stool sampling to obtain a biobank for subsequent microbiota analysis,
  • Cardiovascular exploration based on the measurement of the increase in the diameter of the brachial artery (FMD, "Flow-Mediated Dilation"); measurement of the increase in digital volume (RHI, "Reactive Hyperhemia Index") and measurement of the microcirculatory perfusion of the skin at the level of the hand (FLD, "Flow Laser Doppler"), and measurement of the stiffness of the main arteries (aorta) by the technique of Pulse Wave Velocity (PWV) measurement,
  • Exploration of sarcopenia: the following questionnaires and tests will be performed: SARC-F (Strength, Assistance with walking, Rising from a chair, Climbing stairs, and Falls) and SPPB (Short Physical Performance Battery),
  • Quality of life component questionnaires: Pittsburgh Sleep Quality Index (PSQI), 36-Item Short Form Survey (SF-36), Numerical Pain Scale (NPS), Bref Pain Inventory (BPI), and Hospital Anxiety and Depression scale (HADs).

Visit 2 (T0+1 year) and Visit 4 (T0+3 years): PIC/CIC (1h15)

During this visit, the following examinations, tests and questionnaires will be performed:

  • A physical examination,
  • A blood and stool sample to obtain a collection of biological samples (bone biomarkers, microRNA and microbiota analyses),
  • A cardiovascular exploration with FMD, RHI, FLD and PWV measurements,
  • Exploration of sarcopenia: questionnaires and tests SARC-F, SPPB and measurement of muscle function will be performed,
  • Quality of life component questionnaires: Pittsburgh Sleep Quality Index (PSQI), SF-36 quality of life questionnaire, Numerical Pain Scale (NPS), Bref Pain Inventory (BPI), and Hospital Anxiety and Depression scale (HADs).

Visit 3 (T0+2 years) and visit 5 (T0+4 years): PIC/CIC (1h30)

During this visit, the following examinations, tests and questionnaires will be performed:

  • A physical examination,
  • A blood and stool sample to obtain a collection of biological samples (bone biomarkers, microRNA and microbiota analyses),
  • A cardiovascular exploration with FMD, RHI, FLD and PWV measurements,
  • Exploration of sarcopenia: questionnaires and tests SARC-F, SPPB, measurement of muscle function and DXA with body composition measurement will be performed,
  • Quality of life component questionnaires: Pittsburgh Sleep Quality Index (PSQI), SF-36 quality of life questionnaire, Numerical Pain Scale (NPS), Bref Pain Inventory (BPI), and Hospital Anxiety and Depression scale (HADs).

Visit 5 will be the last visit of the study.

03

Conditions studied

  • Osteoporosis, Postmenopausal

Keywords

  • Osteoporosis
  • Sarcopenia
  • Cardiovascular
  • FMD
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 50 years or older with osteoporosis, whether fractured or not, requiring initiation of treatment with antiosteoporotic drugs (bisphosphonates, raloxifene, teriparatide, denosumab and others to come for this indication, including romosozumab), either orally or by injection, as part of their care and management.
  • Able to give to participate in research.
  • Affiliation to a Social Security system.

Exclusion criteria

Exclusion Criteria:

  • Patient with chronic renal failure, defined as \< 30 mL.min-1 estimated by CKD-EPI.
  • Patient with a medical and/or surgical history deemed by the investigator or his/her representative to be incompatible with the trial.
  • Patient under legal protection or deprived of liberty.
  • Refusal to participate.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Other
    Cohort follow-up

    Exploratory study involving functional explorations in longitudinal follow-up, initiated in parallel with a treatment indicated in the patient's usual care and management.

    Other: Cohort follow-up

Interventions

  • OtherCohort follow-up

    * Inclusion medical consultation, * Inclusion clinical examination, * Collection of biological samples (bone biomarkers, epigenetic biomarkers (microRNA)) and analysis of microbiota and genotyping, * Calculation of the Kauppila score on profile spine radiographs by the rheumatologist, * Cardiovascular investigations (FMD, "Flow-Mediated Dilation"); measurement of digital volume increase (RHI, "Reactive hyperhemia index"); measurement of microcirculatory perfusion of the skin at the hand (FLD, "Flow Laser Doppler") ; measurement of the stiffness of the main arteries (aorta) by the Pulse Wave Velocity (PWV), * Exploration of sarcopenia: questionnaires and tests: SARC-F, SPPB, muscle strength, * Quality of life component questionnaires Pittsburgh Sleep (PSQI), Numerical Scale (NS), Brief Pain Inventory (BPI), Hospital Anxiety and Depression scale (HADs), and 36-Item Short Form Survey (SF-36) Quality of Life Questionnaire.

06

What researchers measure

Primary outcomes

  1. Endothelial dysfunction measured by FMD (Flow-Mediated Dilation) in patients with anti-osteoporotic treatment

    FMD is a non-invasive technique. It was assessed using an ultrasound approach with a high-resolution linear array transducer coupled with computer-assisted analysis software. With this software, changes in the brachial artery could be assessed in real-time through an automated edge detection system. Longitudinal images of the brachial artery were obtained with the transducer fixed on the medial aspect of the dominant arm, approximately 2 cm above the medial epicondyle of the humerus. The transducer was fixed on the arm by a special arm-holding device. The brachial artery diameter was acquired as per a 30 s baseline measure, after which a cuff was placed around forearm (3 cm above wrist) and inflated to 250 mm Hg for 5 min. After cuff deflation, the brachial artery diameter was continuously monitored for 2-4 min to detect the peak artery diameter. FMD was determined as the percentage change in diameter from baseline to peak arterial diameter.

    Time frame: Visit 1: Day 0

  2. Endothelial dysfunction measured by FMD (Flow-Mediated Dilation) in patients with anti-osteoporotic treatment

    FMD is a non-invasive technique. It was assessed using an ultrasound approach with a high-resolution linear array transducer coupled with computer-assisted analysis software. With this software, changes in the brachial artery could be assessed in real-time through an automated edge detection system. Longitudinal images of the brachial artery were obtained with the transducer fixed on the medial aspect of the dominant arm, approximately 2 cm above the medial epicondyle of the humerus. The transducer was fixed on the arm by a special arm-holding device. The brachial artery diameter was acquired as per a 30 s baseline measure, after which a cuff was placed around forearm (3 cm above wrist) and inflated to 250 mm Hg for 5 min. After cuff deflation, the brachial artery diameter was continuously monitored for 2-4 min to detect the peak artery diameter. FMD was determined as the percentage change in diameter from baseline to peak arterial diameter.

    Time frame: Visit 2: Day 0+1 year

  3. Endothelial dysfunction measured by FMD (Flow-Mediated Dilation) in patients with anti-osteoporotic treatment

    FMD is a non-invasive technique. It was assessed using an ultrasound approach with a high-resolution linear array transducer coupled with computer-assisted analysis software. With this software, changes in the brachial artery could be assessed in real-time through an automated edge detection system. Longitudinal images of the brachial artery were obtained with the transducer fixed on the medial aspect of the dominant arm, approximately 2 cm above the medial epicondyle of the humerus. The transducer was fixed on the arm by a special arm-holding device. The brachial artery diameter was acquired as per a 30 s baseline measure, after which a cuff was placed around forearm (3 cm above wrist) and inflated to 250 mm Hg for 5 min. After cuff deflation, the brachial artery diameter was continuously monitored for 2-4 min to detect the peak artery diameter. FMD was determined as the percentage change in diameter from baseline to peak arterial diameter.

    Time frame: Visit 3: Day 0+2 years

  4. Endothelial dysfunction measured by FMD (Flow-Mediated Dilation) in patients with anti-osteoporotic treatment

    FMD is a non-invasive technique. It was assessed using an ultrasound approach with a high-resolution linear array transducer coupled with computer-assisted analysis software. With this software, changes in the brachial artery could be assessed in real-time through an automated edge detection system. Longitudinal images of the brachial artery were obtained with the transducer fixed on the medial aspect of the dominant arm, approximately 2 cm above the medial epicondyle of the humerus. The transducer was fixed on the arm by a special arm-holding device. The brachial artery diameter was acquired as per a 30 s baseline measure, after which a cuff was placed around forearm (3 cm above wrist) and inflated to 250 mm Hg for 5 min. After cuff deflation, the brachial artery diameter was continuously monitored for 2-4 min to detect the peak artery diameter. FMD was determined as the percentage change in diameter from baseline to peak arterial diameter.

    Time frame: Visit 4: Day 0+3 years

  5. Endothelial dysfunction measured by FMD (Flow-Mediated Dilation) in patients with anti-osteoporotic treatment

    FMD is a non-invasive technique. It was assessed using an ultrasound approach with a high-resolution linear array transducer coupled with computer-assisted analysis software. With this software, changes in the brachial artery could be assessed in real-time through an automated edge detection system. Longitudinal images of the brachial artery were obtained with the transducer fixed on the medial aspect of the dominant arm, approximately 2 cm above the medial epicondyle of the humerus. The transducer was fixed on the arm by a special arm-holding device. The brachial artery diameter was acquired as per a 30 s baseline measure, after which a cuff was placed around forearm (3 cm above wrist) and inflated to 250 mm Hg for 5 min. After cuff deflation, the brachial artery diameter was continuously monitored for 2-4 min to detect the peak artery diameter. FMD was determined as the percentage change in diameter from baseline to peak arterial diameter.

    Time frame: Visit 5: Day 0+4 years

Secondary outcomes

  1. Measurement of digital volume increase by RHI (Reactive hyperhemia index), (Endo-PAT2000; Itamar Medical Ltd, Israel).

    RHI is a non-invasive technique. It's measure with a digital plethysmographie device that records pulsatile fluctuations in digital volume at rest and during reactive hyperemia. For the RH-PAT procedure, a peripheral arterial tonometry probe was placed on the right index finger and a control tonometry probe was also placed on the left index finger to eliminate sympathetic nerve effects. In the RH-PAT procedure, the RHI value was calculated as the ratio of the reactive hyperemia between the two hands.

    Time frame: Visit 1: Day 0

  2. Measurement of digital volume increase by RHI (Reactive hyperhemia index), (Endo-PAT2000; Itamar Medical Ltd, Israel).

    RHI is a non-invasive technique. It's measure with a digital plethysmographie device that records pulsatile fluctuations in digital volume at rest and during reactive hyperemia. For the RH-PAT procedure, a peripheral arterial tonometry probe was placed on the right index finger and a control tonometry probe was also placed on the left index finger to eliminate sympathetic nerve effects. In the RH-PAT procedure, the RHI value was calculated as the ratio of the reactive hyperemia between the two hands.

    Time frame: Visit 2: Day 0+1 year

  3. Measurement of digital volume increase by RHI (Reactive hyperhemia index), (Endo-PAT2000; Itamar Medical Ltd, Israel).

    RHI is a non-invasive technique. It's measure with a digital plethysmographie device that records pulsatile fluctuations in digital volume at rest and during reactive hyperemia. For the RH-PAT procedure, a peripheral arterial tonometry probe was placed on the right index finger and a control tonometry probe was also placed on the left index finger to eliminate sympathetic nerve effects. In the RH-PAT procedure, the RHI value was calculated as the ratio of the reactive hyperemia between the two hands.

    Time frame: Visit 3: Day 0+2 years

  4. Measurement of digital volume increase by RHI (Reactive hyperhemia index), (Endo-PAT2000; Itamar Medical Ltd, Israel).

    RHI is a non-invasive technique. It's measure with a digital plethysmographie device that records pulsatile fluctuations in digital volume at rest and during reactive hyperemia. For the RH-PAT procedure, a peripheral arterial tonometry probe was placed on the right index finger and a control tonometry probe was also placed on the left index finger to eliminate sympathetic nerve effects. In the RH-PAT procedure, the RHI value was calculated as the ratio of the reactive hyperemia between the two hands.

    Time frame: Visit 4: Day 0+3 years

  5. Measurement of digital volume increase by RHI (Reactive hyperhemia index), (Endo-PAT2000; Itamar Medical Ltd, Israel).

    RHI is a non-invasive technique. It's measure with a digital plethysmographie device that records pulsatile fluctuations in digital volume at rest and during reactive hyperemia. For the RH-PAT procedure, a peripheral arterial tonometry probe was placed on the right index finger and a control tonometry probe was also placed on the left index finger to eliminate sympathetic nerve effects. In the RH-PAT procedure, the RHI value was calculated as the ratio of the reactive hyperemia between the two hands.

    Time frame: Visit 5: Day 0+4 years

  6. Microcirculation measurement by FLD (Flow Laser Doppler), PeriFlux® (Perimed)

    The Flowmetry by Laser Doppler (FLD) is a non-invasive and validated technique for continuous measurement of the endothelial dependent reactivity in local microcirculation. The flow estimated by this technique is based on the assessment of the Doppler shift of low-power laser light, which is scattered by moving red blood cells. Vascular endothelial function in the micro-vascular compartment is assessed using the laser-doppler system PeriFlux 5010 (Perimed) at the level of the skin of the hands by following the response to a reactive hyperemia induced by a temporary occlusion of the brachial artery (same stimulus as for FMD measurement).

    Time frame: Visit 1: Day 0

  7. Microcirculation measurement by FLD (Flow Laser Doppler), PeriFlux® (Perimed)

    The Flowmetry by Laser Doppler (FLD) is a non-invasive and validated technique for continuous measurement of the endothelial dependent reactivity in local microcirculation. The flow estimated by this technique is based on the assessment of the Doppler shift of low-power laser light, which is scattered by moving red blood cells. Vascular endothelial function in the micro-vascular compartment is assessed using the laser-doppler system PeriFlux 5010 (Perimed) at the level of the skin of the hands by following the response to a reactive hyperemia induced by a temporary occlusion of the brachial artery (same stimulus as for FMD measurement).

    Time frame: Visit 2: Day 0+1 year

  8. Microcirculation measurement by FLD (Flow Laser Doppler), PeriFlux® (Perimed)

    The Flowmetry by Laser Doppler (FLD) is a non-invasive and validated technique for continuous measurement of the endothelial dependent reactivity in local microcirculation. The flow estimated by this technique is based on the assessment of the Doppler shift of low-power laser light, which is scattered by moving red blood cells. Vascular endothelial function in the micro-vascular compartment is assessed using the laser-doppler system PeriFlux 5010 (Perimed) at the level of the skin of the hands by following the response to a reactive hyperemia induced by a temporary occlusion of the brachial artery (same stimulus as for FMD measurement).

    Time frame: Visit 3: Day 0+2 years

  9. Microcirculation measurement by FLD (Flow Laser Doppler), PeriFlux® (Perimed)

    The Flowmetry by Laser Doppler (FLD) is a non-invasive and validated technique for continuous measurement of the endothelial dependent reactivity in local microcirculation. The flow estimated by this technique is based on the assessment of the Doppler shift of low-power laser light, which is scattered by moving red blood cells. Vascular endothelial function in the micro-vascular compartment is assessed using the laser-doppler system PeriFlux 5010 (Perimed) at the level of the skin of the hands by following the response to a reactive hyperemia induced by a temporary occlusion of the brachial artery (same stimulus as for FMD measurement).

    Time frame: Visit 4: Day 0+3 years

  10. Microcirculation measurement by FLD (Flow Laser Doppler), PeriFlux® (Perimed)

    The Flowmetry by Laser Doppler (FLD) is a non-invasive and validated technique for continuous measurement of the endothelial dependent reactivity in local microcirculation. The flow estimated by this technique is based on the assessment of the Doppler shift of low-power laser light, which is scattered by moving red blood cells. Vascular endothelial function in the micro-vascular compartment is assessed using the laser-doppler system PeriFlux 5010 (Perimed) at the level of the skin of the hands by following the response to a reactive hyperemia induced by a temporary occlusion of the brachial artery (same stimulus as for FMD measurement).

    Time frame: Visit 5: Day 0+4 years

  11. Sphygmocor CPV® (Atcor Medical) large artery stiffness measurement (PWV)

    The carotid-femoral Pulse Wave Velocity (PWV) is an established index of arterial stiffness. Pulse, which travels at a higher velocity in stiff arterial vessels, is calculated from measurements of pulse transit time and the distance travelled between the 2 considered recording sites (i.e., carotid artery and femoral artery). The measurements are performed using a validated non-invasive device (SphygmoCor; AtCor Medical Pty. Ltd.) that allows online pulse wave recording and automatic PWV calculation \[PWV = distance (m)/transit time (s)\].

    Time frame: Visit 1: Day 0

  12. Sphygmocor CPV® (Atcor Medical) large artery stiffness measurement (PWV)

    The carotid-femoral Pulse Wave Velocity (PWV) is an established index of arterial stiffness. Pulse, which travels at a higher velocity in stiff arterial vessels, is calculated from measurements of pulse transit time and the distance travelled between the 2 considered recording sites (i.e., carotid artery and femoral artery). The measurements are performed using a validated non-invasive device (SphygmoCor; AtCor Medical Pty. Ltd.) that allows online pulse wave recording and automatic PWV calculation \[PWV = distance (m)/transit time (s)\].

    Time frame: Visit 2: Day 0+1 year

  13. Sphygmocor CPV® (Atcor Medical) large artery stiffness measurement (PWV)

    The carotid-femoral Pulse Wave Velocity (PWV) is an established index of arterial stiffness. Pulse, which travels at a higher velocity in stiff arterial vessels, is calculated from measurements of pulse transit time and the distance travelled between the 2 considered recording sites (i.e., carotid artery and femoral artery). The measurements are performed using a validated non-invasive device (SphygmoCor; AtCor Medical Pty. Ltd.) that allows online pulse wave recording and automatic PWV calculation \[PWV = distance (m)/transit time (s)\].

    Time frame: Visit 3: Day 0+2 years

  14. Sphygmocor CPV® (Atcor Medical) large artery stiffness measurement (PWV)

    The carotid-femoral Pulse Wave Velocity (PWV) is an established index of arterial stiffness. Pulse, which travels at a higher velocity in stiff arterial vessels, is calculated from measurements of pulse transit time and the distance travelled between the 2 considered recording sites (i.e., carotid artery and femoral artery). The measurements are performed using a validated non-invasive device (SphygmoCor; AtCor Medical Pty. Ltd.) that allows online pulse wave recording and automatic PWV calculation \[PWV = distance (m)/transit time (s)\].

    Time frame: Visit 4: Day 0+3 years

  15. Sphygmocor CPV® (Atcor Medical) large artery stiffness measurement (PWV)

    The carotid-femoral Pulse Wave Velocity (PWV) is an established index of arterial stiffness. Pulse, which travels at a higher velocity in stiff arterial vessels, is calculated from measurements of pulse transit time and the distance travelled between the 2 considered recording sites (i.e., carotid artery and femoral artery). The measurements are performed using a validated non-invasive device (SphygmoCor; AtCor Medical Pty. Ltd.) that allows online pulse wave recording and automatic PWV calculation \[PWV = distance (m)/transit time (s)\].

    Time frame: Visit 5: Day 0+4 years

  16. Evaluation of the Abdominal Aorta Calcification (AAC) (Kauppila score)

    The Kauppila score is used to estimate the existence and severity of AAC. This semi-quantitative score is used to assign a score from 0 to 3, depending on the severity of vascular calcification, for the anterior and posterior walls of the aortic vessel wall, opposite each lumbar vertebrae from L1 to L4. A maximum score of 24 is thus obtained.

    Time frame: Preselection visit V0: Day 0-1 month (D0-1)

  17. Evaluation of the Abdominal Aorta Calcification (AAC) (Kauppila score)

    The Kauppila score is used to estimate the existence and severity of AAC. This semi-quantitative score is used to assign a score from 0 to 3, depending on the severity of vascular calcification, for the anterior and posterior walls of the aortic vessel wall, opposite each lumbar vertebrae from L1 to L4. A maximum score of 24 is thus obtained.

    Time frame: Visit 5: Day 0+4 years

  18. Strength, Assistance with walking, Rising from a chair, Climbing stairs, and Falls (SARC-F) questionnaire

    Consists of 5 questions and a score higher than 4 suggests the presence of sarcopenia (or age-related muscular dystrophy). On the other hand, if the score is less than or equal to 3, the patient is diagnosed as "non-sarcopenic" but tests must be repeated regularly in clinical practice.

    Time frame: Visit 1: Day 0

  19. Strength, Assistance with walking, Rising from a chair, Climbing stairs, and Falls (SARC-F) questionnaire

    Consists of 5 questions and a score higher than 4 suggests the presence of sarcopenia (or age-related muscular dystrophy). On the other hand, if the score is less than or equal to 3, the patient is diagnosed as "non-sarcopenic" but tests must be repeated regularly in clinical practice.

    Time frame: Visit 2: Day 0+1 year

  20. Strength, Assistance with walking, Rising from a chair, Climbing stairs, and Falls (SARC-F) questionnaire

    Consists of 5 questions and a score higher than 4 suggests the presence of sarcopenia (or age-related muscular dystrophy). On the other hand, if the score is less than or equal to 3, the patient is diagnosed as "non-sarcopenic" but tests must be repeated regularly in clinical practice.

    Time frame: Visit 3: Day 0+2 years

  21. Strength, Assistance with walking, Rising from a chair, Climbing stairs, and Falls (SARC-F) questionnaire

    Consists of 5 questions and a score higher than 4 suggests the presence of sarcopenia (or age-related muscular dystrophy). On the other hand, if the score is less than or equal to 3, the patient is diagnosed as "non-sarcopenic" but tests must be repeated regularly in clinical practice.

    Time frame: Visit 4: Day 0+3 years

  22. Strength, Assistance with walking, Rising from a chair, Climbing stairs, and Falls (SARC-F) questionnaire

    Consists of 5 questions and a score higher than 4 suggests the presence of sarcopenia (or age-related muscular dystrophy). On the other hand, if the score is less than or equal to 3, the patient is diagnosed as "non-sarcopenic" but tests must be repeated regularly in clinical practice.

    Time frame: Visit 5: Day 0+4 years

  23. Short Physical Performance Battery (SPPB) Questionnaire

    The Short Physical Performance Battery is the sum of the scores on three criteria: the balance test, the walking speed test and the chair lift test. This test is used to evaluate the physical performance of an individual. Adding the scores of all the tests gives an overall performance score. A score below 8 is an indicator of risk of sarcopenia (0-6 low performance 7-9, intermediate; 10-12 high).

    Time frame: Visit 1: Day 0

  24. SPPB Questionnaire

    The Short Physical Performance Battery is the sum of the scores on three criteria: the balance test, the walking speed test and the chair lift test. This test is used to evaluate the physical performance of an individual. Adding the scores of all the tests gives an overall performance score. A score below 8 is an indicator of risk of sarcopenia (0-6 low performance 7-9, intermediate; 10-12 high).

    Time frame: Visit 2: Day 0+1 year

  25. SPPB Questionnaire

    The Short Physical Performance Battery is the sum of the scores on three criteria: the balance test, the walking speed test and the chair lift test. This test is used to evaluate the physical performance of an individual. Adding the scores of all the tests gives an overall performance score. A score below 8 is an indicator of risk of sarcopenia (0-6 low performance 7-9, intermediate; 10-12 high).

    Time frame: Visit 3: Day 0+2 years

  26. SPPB Questionnaire

    The Short Physical Performance Battery is the sum of the scores on three criteria: the balance test, the walking speed test and the chair lift test. This test is used to evaluate the physical performance of an individual. Adding the scores of all the tests gives an overall performance score. A score below 8 is an indicator of risk of sarcopenia (0-6 low performance 7-9, intermediate; 10-12 high).

    Time frame: Visit 4: Day 0+3 years

  27. SPPB Questionnaire

    The Short Physical Performance Battery is the sum of the scores on three criteria: the balance test, the walking speed test and the chair lift test. This test is used to evaluate the physical performance of an individual. Adding the scores of all the tests gives an overall performance score. A score below 8 is an indicator of risk of sarcopenia (0-6 low performance 7-9, intermediate; 10-12 high).

    Time frame: Visit 5: Day 0+4 years

  28. Evaluation of the muscular strength

    A dynamometer measures grip strength, which decreases with age and is associated with more sarcopenia and cardiovascular comorbidities. The dynamometer is held in the dominant hand, in a sitting position, elbow bent at 90°, shoulders relaxed and forearm in a neutral position. The measurement is taken twice and the highest value is retained. Muscle strength is low when the grip strength is less than 27kg for men or 16kg for women.

    Time frame: Visit 1: Day 0

  29. Evaluation of the muscular strength

    A dynamometer measures grip strength, which decreases with age and is associated with more sarcopenia and cardiovascular comorbidities. The dynamometer is held in the dominant hand, in a sitting position, elbow bent at 90°, shoulders relaxed and forearm in a neutral position. The measurement is taken twice and the highest value is retained. Muscle strength is low when the grip strength is less than 27kg for men or 16kg for women.

    Time frame: Visit 2: Day 0+1 year

  30. Evaluation of the muscular strength

    A dynamometer measures grip strength, which decreases with age and is associated with more sarcopenia and cardiovascular comorbidities. The dynamometer is held in the dominant hand, in a sitting position, elbow bent at 90°, shoulders relaxed and forearm in a neutral position. The measurement is taken twice and the highest value is retained. Muscle strength is low when the grip strength is less than 27kg for men or 16kg for women.

    Time frame: Visit 3: Day 0+2 years

  31. Evaluation of the muscular strength

    A dynamometer measures grip strength, which decreases with age and is associated with more sarcopenia and cardiovascular comorbidities. The dynamometer is held in the dominant hand, in a sitting position, elbow bent at 90°, shoulders relaxed and forearm in a neutral position. The measurement is taken twice and the highest value is retained. Muscle strength is low when the grip strength is less than 27kg for men or 16kg for women.

    Time frame: Visit 4: Day 0+3 years

  32. Evaluation of the muscular strength

    A dynamometer measures grip strength, which decreases with age and is associated with more sarcopenia and cardiovascular comorbidities. The dynamometer is held in the dominant hand, in a sitting position, elbow bent at 90°, shoulders relaxed and forearm in a neutral position. The measurement is taken twice and the highest value is retained. Muscle strength is low when the grip strength is less than 27kg for men or 16kg for women.

    Time frame: Visit 5: Day 0+4 years

  33. Body composition measurement on Dual energy X-ray Absorptiometry (DXA)

    Body composition analysis by DXA, and quantification of appendicular muscle mass, is the reference method for the diagnosis of sarcopenia. It consists of measuring the appendicular skeletal mass (ASM), i.e. the muscle mass of the upper and lower limbs, or the ASM index (ASMI = ASM/height2). Sarcopenia is confirmed when the MSA is less than 20kg in men and 15kg in women or when the ASMI is less than 7kg/m2 in men and 5.5kg/m2 in women.

    Time frame: Preselection visit V0: Day 0-1 month (D0-1)

  34. Body composition measurement on Dual energy X-ray Absorptiometry (DXA)

    Body composition analysis by DXA, and quantification of appendicular muscle mass, is the reference method for the diagnosis of sarcopenia. It consists of measuring the appendicular skeletal mass (ASM), i.e. the muscle mass of the upper and lower limbs, or the ASM index (ASMI = ASM/height2). Sarcopenia is confirmed when the MSA is less than 20kg in men and 15kg in women or when the ASMI is less than 7kg/m2 in men and 5.5kg/m2 in women.

    Time frame: Visit 3: Day 0+2 years

  35. Body composition measurement on Dual energy X-ray Absorptiometry (DXA)

    Body composition analysis by DXA, and quantification of appendicular muscle mass, is the reference method for the diagnosis of sarcopenia. It consists of measuring the appendicular skeletal mass (ASM), i.e. the muscle mass of the upper and lower limbs, or the ASM index (ASMI = ASM/height2). Sarcopenia is confirmed when the MSA is less than 20kg in men and 15kg in women or when the ASMI is less than 7kg/m2 in men and 5.5kg/m2 in women.

    Time frame: Visit 5: Day 0+4 years

  36. The Pittsburgh Sleep Quality Index (PSQI)

    The PSQI is a self-administered questionnaire with 19 items. It was developed to measure sleep quality in the month prior to the patient interview. This questionnaire includes 7 components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, hypnotic medication use and daytime dysfunction. The global score (0 to 21) is obtained by adding the sub-scores of the 7 components, each ranging from 0 to 3 points. In the absence of an answer to one or more questions, the subtotal using this question cannot be calculated and will affect the overall score. The higher the overall score, the greater the impairment in sleep quality. An overall score \>5 is an indicator of sleep disturbance.

    Time frame: Visit 1: Day 0

  37. The Pittsburgh Sleep Quality Index (PSQI)

    The PSQI is a self-administered questionnaire with 19 items. It was developed to measure sleep quality in the month prior to the patient interview. This questionnaire includes 7 components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, hypnotic medication use and daytime dysfunction. The global score (0 to 21) is obtained by adding the sub-scores of the 7 components, each ranging from 0 to 3 points. In the absence of an answer to one or more questions, the subtotal using this question cannot be calculated and will affect the overall score. The higher the overall score, the greater the impairment in sleep quality. An overall score \>5 is an indicator of sleep disturbance.

    Time frame: Visit 2: Day 0+1 year

  38. The Pittsburgh Sleep Quality Index (PSQI)

    The PSQI is a self-administered questionnaire with 19 items. It was developed to measure sleep quality in the month prior to the patient interview. This questionnaire includes 7 components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, hypnotic medication use and daytime dysfunction. The global score (0 to 21) is obtained by adding the sub-scores of the 7 components, each ranging from 0 to 3 points. In the absence of an answer to one or more questions, the subtotal using this question cannot be calculated and will affect the overall score. The higher the overall score, the greater the impairment in sleep quality. An overall score \>5 is an indicator of sleep disturbance.

    Time frame: Visit 3: Day 0+2 years

  39. The Pittsburgh Sleep Quality Index (PSQI)

    The PSQI is a self-administered questionnaire with 19 items. It was developed to measure sleep quality in the month prior to the patient interview. This questionnaire includes 7 components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, hypnotic medication use and daytime dysfunction. The global score (0 to 21) is obtained by adding the sub-scores of the 7 components, each ranging from 0 to 3 points. In the absence of an answer to one or more questions, the subtotal using this question cannot be calculated and will affect the overall score. The higher the overall score, the greater the impairment in sleep quality. An overall score \>5 is an indicator of sleep disturbance.

    Time frame: Visit 4: Day 0+3 years

  40. The Pittsburgh Sleep Quality Index (PSQI)

    The PSQI is a self-administered questionnaire with 19 items. It was developed to measure sleep quality in the month prior to the patient interview. This questionnaire includes 7 components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, hypnotic medication use and daytime dysfunction. The global score (0 to 21) is obtained by adding the sub-scores of the 7 components, each ranging from 0 to 3 points. In the absence of an answer to one or more questions, the subtotal using this question cannot be calculated and will affect the overall score. The higher the overall score, the greater the impairment in sleep quality. An overall score \>5 is an indicator of sleep disturbance.

    Time frame: Visit 5: Day 0+4 years

  41. The Brief Pain Inventory Questionnaire (BPI)

    This self-assessment scale allows the patient to characterize the pain in terms of its intensity and its psychosocial repercussions by means of 11 scales rated from 0 (no pain or does not bother) to 10 (the most horrible pain you can imagine or completely bothers you). The QCD also asks the patient to black out the painful areas on a diagram (front and back) and to put an "S" if the pain is on the surface or a "P" if it is deep. The questionnaire also asks the patient to indicate what treatment or medication he or she is taking for the pain and what percentage improvement has been obtained.

    Time frame: Visit 1: Day 0

  42. The Brief Pain Inventory Questionnaire (BPI)

    This self-assessment scale allows the patient to characterize the pain in terms of its intensity and its psychosocial repercussions by means of 11 scales rated from 0 (no pain or does not bother) to 10 (the most horrible pain you can imagine or completely bothers you). The QCD also asks the patient to black out the painful areas on a diagram (front and back) and to put an "S" if the pain is on the surface or a "P" if it is deep. The questionnaire also asks the patient to indicate what treatment or medication he or she is taking for the pain and what percentage improvement has been obtained.

    Time frame: Visit 2: Day 0+1 year

  43. The Brief Pain Inventory Questionnaire (BPI)

    This self-assessment scale allows the patient to characterize the pain in terms of its intensity and its psychosocial repercussions by means of 11 scales rated from 0 (no pain or does not bother) to 10 (the most horrible pain you can imagine or completely bothers you). The QCD also asks the patient to black out the painful areas on a diagram (front and back) and to put an "S" if the pain is on the surface or a "P" if it is deep. The questionnaire also asks the patient to indicate what treatment or medication he or she is taking for the pain and what percentage improvement has been obtained.

    Time frame: Visit 3: Day 0+2 years

  44. The Brief Pain Inventory Questionnaire (BPI)

    This self-assessment scale allows the patient to characterize the pain in terms of its intensity and its psychosocial repercussions by means of 11 scales rated from 0 (no pain or does not bother) to 10 (the most horrible pain you can imagine or completely bothers you). The QCD also asks the patient to black out the painful areas on a diagram (front and back) and to put an "S" if the pain is on the surface or a "P" if it is deep. The questionnaire also asks the patient to indicate what treatment or medication he or she is taking for the pain and what percentage improvement has been obtained.

    Time frame: Visit 4: Day 0+3 years

  45. The Brief Pain Inventory Questionnaire (BPI)

    This self-assessment scale allows the patient to characterize the pain in terms of its intensity and its psychosocial repercussions by means of 11 scales rated from 0 (no pain or does not bother) to 10 (the most horrible pain you can imagine or completely bothers you). The QCD also asks the patient to black out the painful areas on a diagram (front and back) and to put an "S" if the pain is on the surface or a "P" if it is deep. The questionnaire also asks the patient to indicate what treatment or medication he or she is taking for the pain and what percentage improvement has been obtained.

    Time frame: Visit 5: Day 0+4 years

  46. The numerical pain scale

    This scale allows the patient to rate the pain on a scale with a minimum score of 0 (no pain) and a maximum score of 10 (worst pain).

    Time frame: Visit 1: Day 0

  47. The numerical pain scale

    This scale allows the patient to rate the pain on a scale with a minimum score of 0 (no pain) and a maximum score of 10 (worst pain).

    Time frame: Visit 2: Day 0+1 year

  48. The numerical pain scale

    This scale allows the patient to rate the pain on a scale with a minimum score of 0 (no pain) and a maximum score of 10 (worst pain).

    Time frame: Visit 3: Day 0+2 years

  49. The numerical pain scale

    This scale allows the patient to rate the pain on a scale with a minimum score of 0 (no pain) and a maximum score of 10 (worst pain).

    Time frame: Visit 4: Day 0+3 years

  50. The numerical pain scale

    This scale allows the patient to rate the pain on a scale with a minimum score of 0 (no pain) and a maximum score of 10 (worst pain).

    Time frame: Visit 5: Day 0+4 years

  51. The Hospital Anxiety and Depression Scale (HAD)

    It is a self-administered questionnaire completed by the patient and based on the Hamilton scale. The HAD scale is a tool for screening for anxiety and depressive disorders. It includes 14 items rated from 0 to 3. Seven questions relate to anxiety (total A) and seven others to the depressive dimension (total D), thus making it possible to obtain two scores (maximum score for each score = 21). To screen for anxiety and depressive symptomatology, the following interpretation can be proposed for each of the scores (A and D): ≤ 7: normal case; 8 to 10: borderline case; ≥ 11: abnormal case.

    Time frame: Visit 1: Day 0

  52. The Hospital Anxiety and Depression Scale (HAD)

    It is a self-administered questionnaire completed by the patient and based on the Hamilton scale. The HAD scale is a tool for screening for anxiety and depressive disorders. It includes 14 items rated from 0 to 3. Seven questions relate to anxiety (total A) and seven others to the depressive dimension (total D), thus making it possible to obtain two scores (maximum score for each score = 21). To screen for anxiety and depressive symptomatology, the following interpretation can be proposed for each of the scores (A and D): ≤ 7: normal case; 8 to 10: borderline case; ≥ 11: abnormal case.

    Time frame: Visit 2: Day 0+1 year

  53. The Hospital Anxiety and Depression Scale (HAD)

    It is a self-administered questionnaire completed by the patient and based on the Hamilton scale. The HAD scale is a tool for screening for anxiety and depressive disorders. It includes 14 items rated from 0 to 3. Seven questions relate to anxiety (total A) and seven others to the depressive dimension (total D), thus making it possible to obtain two scores (maximum score for each score = 21). To screen for anxiety and depressive symptomatology, the following interpretation can be proposed for each of the scores (A and D): ≤ 7: normal case; 8 to 10: borderline case; ≥ 11: abnormal case.

    Time frame: Visit 3: Day 0+2 years

  54. The Hospital Anxiety and Depression Scale (HAD)

    It is a self-administered questionnaire completed by the patient and based on the Hamilton scale. The HAD scale is a tool for screening for anxiety and depressive disorders. It includes 14 items rated from 0 to 3. Seven questions relate to anxiety (total A) and seven others to the depressive dimension (total D), thus making it possible to obtain two scores (maximum score for each score = 21). To screen for anxiety and depressive symptomatology, the following interpretation can be proposed for each of the scores (A and D): ≤ 7: normal case; 8 to 10: borderline case; ≥ 11: abnormal case.

    Time frame: Visit 4: Day 0+3 years

  55. The Hospital Anxiety and Depression Scale (HAD)

    It is a self-administered questionnaire completed by the patient and based on the Hamilton scale. The HAD scale is a tool for screening for anxiety and depressive disorders. It includes 14 items rated from 0 to 3. Seven questions relate to anxiety (total A) and seven others to the depressive dimension (total D), thus making it possible to obtain two scores (maximum score for each score = 21). To screen for anxiety and depressive symptomatology, the following interpretation can be proposed for each of the scores (A and D): ≤ 7: normal case; 8 to 10: borderline case; ≥ 11: abnormal case.

    Time frame: Visit 5: Day 0+4 years

  56. The 36-Item Short Form Survey (SF-36)

    The quality of life of patients is assessed by the general questionnaire 36-Item Short Form Survey (SF-36) which can be administered by self or hetero-questionnaire. The SF-36 questionnaire was developed from the Medical Outcome Study, a 149-item questionnaire that was developed to assess how the American healthcare system affects the outcome of care. The SF-36 questionnaire is composed of 36 items and makes it possible to assess the physical and mental health of an individual using eleven questions relating to eight aspects of health: Physical activity, limitations due to physical state, physical pain, perceived health, vitality, life and relationship with others, limitations due to the mental state and mental health. Scores between 0 and 100 are determined. Scores tending towards 100 indicate a better quality of life.

    Time frame: Visit 1: Day 0

  57. The 36-Item Short Form Survey (SF-36)

    The quality of life of patients is assessed by the general questionnaire 36-Item Short Form Survey (SF-36) which can be administered by self or hetero-questionnaire. The SF-36 questionnaire was developed from the Medical Outcome Study, a 149-item questionnaire that was developed to assess how the American healthcare system affects the outcome of care. The SF-36 questionnaire is composed of 36 items and makes it possible to assess the physical and mental health of an individual using eleven questions relating to eight aspects of health: Physical activity, limitations due to physical state, physical pain, perceived health, vitality, life and relationship with others, limitations due to the mental state and mental health. Scores between 0 and 100 are determined. Scores tending towards 100 indicate a better quality of life.

    Time frame: Visit 2: Day 0+1 year

  58. The 36-Item Short Form Survey (SF-36)

    The quality of life of patients is assessed by the general questionnaire 36-Item Short Form Survey (SF-36) which can be administered by self or hetero-questionnaire. The SF-36 questionnaire was developed from the Medical Outcome Study, a 149-item questionnaire that was developed to assess how the American healthcare system affects the outcome of care. The SF-36 questionnaire is composed of 36 items and makes it possible to assess the physical and mental health of an individual using eleven questions relating to eight aspects of health: Physical activity, limitations due to physical state, physical pain, perceived health, vitality, life and relationship with others, limitations due to the mental state and mental health. Scores between 0 and 100 are determined. Scores tending towards 100 indicate a better quality of life.

    Time frame: Visit 3: Day 0+2 years

  59. The 36-Item Short Form Survey (SF-36)

    The quality of life of patients is assessed by the general questionnaire 36-Item Short Form Survey (SF-36) which can be administered by self or hetero-questionnaire. The SF-36 questionnaire was developed from the Medical Outcome Study, a 149-item questionnaire that was developed to assess how the American healthcare system affects the outcome of care. The SF-36 questionnaire is composed of 36 items and makes it possible to assess the physical and mental health of an individual using eleven questions relating to eight aspects of health: Physical activity, limitations due to physical state, physical pain, perceived health, vitality, life and relationship with others, limitations due to the mental state and mental health. Scores between 0 and 100 are determined. Scores tending towards 100 indicate a better quality of life.

    Time frame: Visit 4: Day 0+3 years

  60. The 36-Item Short Form Survey (SF-36)

    The quality of life of patients is assessed by the general questionnaire 36-Item Short Form Survey (SF-36) which can be administered by self or hetero-questionnaire. The SF-36 questionnaire was developed from the Medical Outcome Study, a 149-item questionnaire that was developed to assess how the American healthcare system affects the outcome of care. The SF-36 questionnaire is composed of 36 items and makes it possible to assess the physical and mental health of an individual using eleven questions relating to eight aspects of health: Physical activity, limitations due to physical state, physical pain, perceived health, vitality, life and relationship with others, limitations due to the mental state and mental health. Scores between 0 and 100 are determined. Scores tending towards 100 indicate a better quality of life.

    Time frame: Visit 5: Day 0+4 years

  61. Sclerostin dosage

    The dosage of slerostin (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes

    Time frame: Visit 1: Day 0

  62. Sclerostin dosage

    The dosage of slerostin (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes

    Time frame: Visit 2: Day 0+1 year

  63. Sclerostin dosage

    The dosage of slerostin (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes

    Time frame: Visit 3: Day 0+2 years

  64. Sclerostin dosage

    The dosage of slerostin (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes

    Time frame: Visit 4: Day 0+3 years

  65. Sclerostin dosage

    The dosage of slerostin (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes

    Time frame: Visit 5: Day 0+4 years

  66. Osteocalcin dosage

    The dosage of osteocalcin (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes

    Time frame: Visit 1: Day 0

  67. Osteocalcin dosage

    The dosage of osteocalcin (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes

    Time frame: Visit 2: Day 0+1 year

  68. Osteocalcin dosage

    The dosage of osteocalcin (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes

    Time frame: Visit 3: Day 0+2 years

  69. Osteocalcin dosage

    The dosage of osteocalcin (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes

    Time frame: Visit 4: Day 0+3 years

  70. Osteocalcin dosage

    The dosage of osteocalcin (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes

    Time frame: Visit 5: Day 0+4 years

  71. Periostin dosage

    The dosage of periostin (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes

    Time frame: Visit 1: Day 0

  72. Periostin dosage

    The dosage of periostin (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes

    Time frame: Visit 2: Day 0+1 year

  73. Periostin dosage

    The dosage of periostin (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes

    Time frame: Visit 3: Day 0+2 years

  74. Periostin dosage

    The dosage of periostin (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes

    Time frame: Visit 4: Day 0+3 years

  75. Periostin dosage

    The dosage of periostin (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes

    Time frame: Visit 5: Day 0+4 years

  76. Irisin dosage

    The dosage of irisin (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken on 4 mL heparin tube for irisin dosage.

    Time frame: Visit 1: Day 0

  77. Irisin dosage

    The dosage of irisin (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken on 4 mL heparin tube for irisin dosage.

    Time frame: Visit 2: Day 0+1 year

  78. Irisin dosage

    The dosage of irisin (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken on 4 mL heparin tube for irisin dosage.

    Time frame: Visit 3: Day 0+2 years

  79. Irisin dosage

    The dosage of irisin (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken on 4 mL heparin tube for irisin dosage.

    Time frame: Visit 4: Day 0+3 years

  80. Irisin dosage

    The dosage of irisin (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken on 4 mL heparin tube for irisin dosage.

    Time frame: Visit 5: Day 0+4 years

  81. N-terminal propeptide of procollagen type 1 (P1NP) dosage

    The dosage of N-terminal propeptide of procollagen type 1 (P1NP) (µg/l) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes

    Time frame: Visit 1: Day 0

  82. N-terminal propeptide of procollagen type 1 (P1NP) dosage

    The dosage of N-terminal propeptide of procollagen type 1 (P1NP) (µg/l) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes

    Time frame: Visit 2: Day 0+1 year

  83. N-terminal propeptide of procollagen type 1 (P1NP) dosage

    The dosage of N-terminal propeptide of procollagen type 1 (P1NP) (µg/l) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes

    Time frame: Visit 3: Day 0+2 years

  84. N-terminal propeptide of procollagen type 1 (P1NP) dosage

    The dosage of N-terminal propeptide of procollagen type 1 (P1NP) (µg/l) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes

    Time frame: Visit 4: Day 0+3 years

  85. N-terminal propeptide of procollagen type 1 (P1NP) dosage

    The dosage of N-terminal propeptide of procollagen type 1 (P1NP) (µg/l) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes

    Time frame: Visit 5: Day 0+4 years

  86. Dickkopf-related protein 1 (DKK1) dosage

    The dosage of Dickkopf-related protein 1 (DKK1) (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes

    Time frame: Visit 1: Day 0

  87. Dickkopf-related protein 1 (DKK1) dosage

    The dosage of Dickkopf-related protein 1 (DKK1) (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes

    Time frame: Visit 2: Day 0+1 year

  88. Dickkopf-related protein 1 (DKK1) dosage

    The dosage of Dickkopf-related protein 1 (DKK1) (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes

    Time frame: Visit 3: Day 0+2 years

  89. Dickkopf-related protein 1 (DKK1) dosage

    The dosage of Dickkopf-related protein 1 (DKK1) (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes

    Time frame: Visit 4: Day 0+3 years

  90. Dickkopf-related protein 1 (DKK1) dosage

    The dosage of Dickkopf-related protein 1 (DKK1) (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes

    Time frame: Visit 5: Day 0+4 years

  91. C-terminal telopeptides of collagen type 1 (CTX) dosage

    The dosage of C-terminal telopeptides of collagen type 1 (CTX) (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes

    Time frame: Visit 1: Day 0

  92. C-terminal telopeptides of collagen type 1 (CTX) dosage

    The dosage of C-terminal telopeptides of collagen type 1 (CTX) (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes

    Time frame: Visit 2: Day 0+1 year

  93. C-terminal telopeptides of collagen type 1 (CTX) dosage

    The dosage of C-terminal telopeptides of collagen type 1 (CTX) (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes

    Time frame: Visit 3: Day 0+2 years

  94. C-terminal telopeptides of collagen type 1 (CTX) dosage

    The dosage of C-terminal telopeptides of collagen type 1 (CTX) (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes

    Time frame: Visit 4: Day 0+3 years

  95. C-terminal telopeptides of collagen type 1 (CTX) dosage

    The dosage of C-terminal telopeptides of collagen type 1 (CTX) (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes

    Time frame: Visit 5: Day 0+4 years

  96. Distribution of gene polymorphisms using OpenArray technology

    Blood sampling: 4 aliquots of 1 ml will be taken from the whole blood sample on EDTA tube, then frozen at -80°C in the premises of the PIC/CIC Inserm 1405, Clermont-Ferrand, France for subsequent analysis.

    Time frame: Visit 1: Day 0

  97. MicroRNA analysis using OpenArray technology

    Blood sampling: 1 EDTA tube of 6 ml will be collected for microRNA. The tube will then be centrifuged and 6 aliquots of 0.5 ml will be prepared (centrifugation 2500G/ 10 min/4°C) then frozen and stored at - 80°C in the premises of the PIC/CIC Inserm 1405, Clermont-Ferrand, France for subsequent analysis.

    Time frame: Visit 1: Day 0

  98. MicroRNA analysis using OpenArray technology

    Blood sampling: 1 EDTA tube of 6 ml will be collected for microRNA. The tube will then be centrifuged and 6 aliquots of 0.5 ml will be prepared (centrifugation 2500G/ 10 min/4°C) then frozen and stored at - 80°C in the premises of the PIC/CIC Inserm 1405, Clermont-Ferrand, France for subsequent analysis.

    Time frame: Visit 2: Day 0+1 year

  99. MicroRNA analysis using OpenArray technology

    Blood sampling: 1 EDTA tube of 6 ml will be collected for microRNA. The tube will then be centrifuged and 6 aliquots of 0.5 ml will be prepared (centrifugation 2500G/ 10 min/4°C) then frozen and stored at - 80°C in the premises of the PIC/CIC Inserm 1405, Clermont-Ferrand, France for subsequent analysis.

    Time frame: Visit 3: Day 0+2 years

  100. MicroRNA analysis using OpenArray technology

    Blood sampling: 1 EDTA tube of 6 ml will be collected for microRNA. The tube will then be centrifuged and 6 aliquots of 0.5 ml will be prepared (centrifugation 2500G/ 10 min/4°C) then frozen and stored at - 80°C in the premises of the PIC/CIC Inserm 1405, Clermont-Ferrand, France for subsequent analysis.

    Time frame: Visit 4: Day 0+3 years

  101. MicroRNA analysis using OpenArray technology

    Blood sampling: 1 EDTA tube of 6 ml will be collected for microRNA. The tube will then be centrifuged and 6 aliquots of 0.5 ml will be prepared (centrifugation 2500G/ 10 min/4°C) then frozen and stored at - 80°C in the premises of the PIC/CIC Inserm 1405, Clermont-Ferrand, France for subsequent analysis.

    Time frame: Visit 5: Day 0+4 years

  102. Study of the microbiota

    Stool sampling in order to study the microbiota. The patient must collect the stool at each visit by following the technical instructions described in the explanatory leaflet that will be provided. She must then respect the procedure for the conservation and transport of the stool described in this document. The samples will be stored at the PIC/ CIC Inserm 1405, Clermont-Ferrand, Franced for subsequent analysis.

    Time frame: Visit 1: Day 0

  103. Study of the microbiota

    Stool sampling in order to study the microbiota. The patient must collect the stool at each visit by following the technical instructions described in the explanatory leaflet that will be provided. She must then respect the procedure for the conservation and transport of the stool described in this document. The samples will be stored at the PIC/ CIC Inserm 1405, Clermont-Ferrand, Franced for subsequent analysis.

    Time frame: Visit 2: Day 0+1 year

  104. Study of the microbiota

    Stool sampling in order to study the microbiota. The patient must collect the stool at each visit by following the technical instructions described in the explanatory leaflet that will be provided. She must then respect the procedure for the conservation and transport of the stool described in this document. The samples will be stored at the PIC/ CIC Inserm 1405, Clermont-Ferrand, Franced for subsequent analysis.

    Time frame: Visit 3: Day 0+2 years

  105. Study of the microbiota

    Stool sampling in order to study the microbiota. The patient must collect the stool at each visit by following the technical instructions described in the explanatory leaflet that will be provided. She must then respect the procedure for the conservation and transport of the stool described in this document. The samples will be stored at the PIC/ CIC Inserm 1405, Clermont-Ferrand, Franced for subsequent analysis.

    Time frame: Visit 4: Day 0+3 years

  106. Study of the microbiota

    Stool sampling in order to study the microbiota. The patient must collect the stool at each visit by following the technical instructions described in the explanatory leaflet that will be provided. She must then respect the procedure for the conservation and transport of the stool described in this document. The samples will be stored at the PIC/ CIC Inserm 1405, Clermont-Ferrand, Franced for subsequent analysis.

    Time frame: Visit 5: Day 0+4 years

  107. Identification of predictive factors of treatment effectiveness according to variations in vascular and endothelial function parameters and pain, which will be studied first as quantitative parameters and then as categorical data.

    This parameter will be evaluated according to a statiscal method on all the data collected throughout the study. This statistical method will allow to obtain different trajectories corresponding to therapeutic response profile.

    Time frame: Through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for Feb 2027, 59 months after the start.

Of 48 non-industry interventional studies with no phase under Osteoporosis, Postmenopausal, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 34. This study's planned 59 months is above that.

Counting every sponsor, half of 51 studies reached it within 17 months; a quarter within 9 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2022
First posted
Feb 8, 2022
StartActual
Feb 15, 2022
Primary completionEst.
Feb 1, 2027
CompletionEst.
Feb 1, 2027
Last update
Oct 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05228262
Responsible party
Sponsor
First posted
Feb 8, 2022
Start date
Feb 15, 2022
Primary completion
Feb 1, 2027 (estimated)
Completion
Feb 1, 2027 (estimated)
Last update
Oct 10, 2022

Study contacts

Lise LACLAUTRE
Contact
promo_interne_drci@chu-clermontferrand.fr
+33473754963
Marie-Eva Pickering
principal investigator · University Hospital, Clermont-Ferrand

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion